Key takeaways

  • OncoSil Medical (ASX:OSL) presented updated results from its Phase II TRIPP-FFX study at the ESMO Gastrointestinal Cancers Congress (ESMO GI 2026) in Munich, Germany, on 6 July 2026.
  • The study, which combined the OncoSil device with FOLFIRINOX chemotherapy in unresectable locally advanced pancreatic cancer (LAPC), reported it had met both co-primary endpoints covering safety and local disease control.
  • A newly reported Per Protocol analysis showed a median overall survival of 21.3 months in the combination arm, alongside an intent-to-treat median overall survival of 18.2 months.
  • Management indicated it plans to submit a Change Notification to its EU and UK Notified Body later in the second half of 2026, seeking to expand the device label to include the FOLFIRINOX combination.

OncoSil Medical Limited (ASX:OSL) is an ASX-listed medical device company developing a brachytherapy device for the treatment of locally advanced pancreatic cancer, a disease with very limited effective treatment options. The company has been conducting clinical studies including the TRIPP-FFX trial, examining its OncoSil device in combination with chemotherapy. The company recently released data from the TRIPP-FFX study that provided clinical evidence on the device's performance in a combination treatment setting. Shares in OncoSil Medical were trading higher at the time of writing on 23 July 2026, as investors responded to the clinical data update.

What OncoSil announced

OncoSil Medical presented updated results from its TRIPP-FFX study at ESMO GI 2026, the European Society for Medical Oncology's Gastrointestinal Cancers Congress, held in Munich, Germany. According to the company, the data were delivered on 6 July 2026 as a Rapid Oral Presentation by Professor Michele Milella of the University of Verona, a co-principal investigator on the study.

TRIPP-FFX is a Phase II study evaluating the OncoSil device used together with FOLFIRINOX, a widely used combination chemotherapy regimen, in patients with unresectable locally advanced pancreatic cancer. LAPC describes tumours that have grown into surrounding structures such that they cannot be surgically removed, but which have not yet spread widely to distant organs. It is a setting with limited treatment options and historically poor survival outcomes.

The company said the study met both of its co-primary endpoints: safety and tolerability, and local disease control rate (LDCR) measured at 16 weeks. OncoSil reported that no new safety signals were identified in the analysis, consistent with the device's established safety profile.

The presentation's headline feature was a newly reported Per Protocol analysis, which examines outcomes among patients who received treatment as intended under the study protocol. This sits alongside the intent-to-treat analysis, which includes all enrolled patients regardless of how much treatment they ultimately received.

The clinical detail

On the co-primary local disease control endpoint, OncoSil reported an LDCR at 16 weeks of 82.2% in the intent-to-treat population (95% confidence interval 67.9-92.0%) and 85.0% in the Per Protocol population (95% confidence interval 70.2-94.3%).

On survival, the company reported an intent-to-treat median overall survival of 18.2 months, with a median local progression-free survival of 12.8 months and a median progression-free survival of 12.1 months. The newly reported Per Protocol analysis showed a median overall survival of 21.3 months.

OncoSil also pointed to comparative and secondary measures from the study. In figures reported for the combination against FOLFIRINOX chemotherapy alone, the company cited a surgical resection rate of 12.5% in the OncoSil-treated group versus 7.3% in the comparator, an R0 (complete) resection rate of 60% versus 33% among those resected, and a tumour volume reduction of 72.2% versus 55.9%.

These numbers describe a treatment effect that management characterised as encouraging in a disease where median survival has historically been measured in months rather than years. It is important to note, however, that TRIPP-FFX is a Phase II study, and cross-study or arm-level comparisons of this kind should be interpreted with caution given differences in patient populations, sample sizes and study design.

CEO Nigel Lange said the presentation reinforced the clinical case for the device. "This new analysis further strengthens the clinical evidence supporting the use of the OncoSil device alongside FOLFIRINOX in patients with unresectable LAPC," he said, adding that the Per Protocol analysis "demonstrated a median overall survival of 21.3 months together with encouraging efficacy outcomes."

How the OncoSil device works

The OncoSil device is a targeted internal radiation therapy built around phosphorus-32 (P-32), a radioactive isotope contained within microparticles. The particles are implanted directly into a pancreatic tumour under image guidance, where the isotope delivers localised beta radiation over time as it decays. The approach is designed to concentrate radiation within the tumour while limiting exposure to surrounding healthy tissue, and it is used in combination with systemic chemotherapy rather than as a standalone treatment.

The device carries CE Mark approval in Europe for the treatment of unresectable locally advanced pancreatic cancer, and OncoSil has previously secured regulatory clearances in other markets, including Australia. TRIPP-FFX forms part of the company's strategy to build clinical evidence specifically around the device's use with FOLFIRINOX, one of the standard chemotherapy backbones in pancreatic cancer.

Potential opportunities and positive factors

For investors, the most tangible opportunity flagged by the company is regulatory. OncoSil said it plans to submit a Change Notification to its EU and UK Notified Body later in the second half of 2026, seeking to expand the device's label to formally include use in combination with FOLFIRINOX. A broader, more specific label could support commercial adoption in a setting where clinicians already use FOLFIRINOX as a chemotherapy backbone.

The clinical data themselves represent the other pillar of the positive case. Meeting both co-primary endpoints, reporting no new safety signals, and generating survival figures that management describes as encouraging all add to the evidence base that OncoSil can present to regulators, clinicians and payers. Presentation at a recognised international congress such as ESMO GI, delivered by an independent academic investigator, also lends external visibility to the results.

More broadly, pancreatic cancer remains an area of high unmet medical need, and locally advanced disease is a segment where few effective options exist. A device that can demonstrate consistent local disease control alongside standard chemotherapy could, if supported by continued evidence and regulatory progress, address a meaningful clinical gap.

Material risks and uncertainties

The risks facing OncoSil are substantial and typical of a small, pre-commercial-scale medical technology company. TRIPP-FFX is a Phase II study, and encouraging Phase II results do not guarantee success in larger confirmatory trials or automatic regulatory or commercial outcomes. Per Protocol analyses, by design, exclude some enrolled patients and can present a more favourable picture than intent-to-treat data; the intent-to-treat median overall survival of 18.2 months, while also positive, is the more conservative reference point.

Comparisons between the OncoSil-plus-FOLFIRINOX group and chemotherapy alone should be read carefully given the study's size and design, and the confidence intervals around key survival estimates are wide, reflecting relatively small patient numbers. The planned Change Notification is subject to regulatory review, and there is no certainty that a Notified Body will approve an expanded label, or on what timeline.

What investors may watch next

Several clear milestones lie ahead. The most concrete is the planned Change Notification submission to the EU and UK Notified Body, expected later in the second half of 2026, and any subsequent updates on its progress. Investors may also watch for full publication of the TRIPP-FFX results in a peer-reviewed journal, further data readouts or longer-term follow-up, and any commentary on commercial adoption or reimbursement in markets where the device is already approved.

Beyond the specific study, updates on the company's cash position, funding arrangements and broader clinical strategy will be relevant to assessing whether OncoSil can convert clinical progress into a sustainable commercial position.

OncoSil Medical (ASX:OSL) has added to its clinical evidence base with updated TRIPP-FFX data presented at ESMO GI 2026, reporting that its phosphorus-32 device combined with FOLFIRINOX met both co-primary endpoints in locally advanced pancreatic cancer and produced survival figures the company views as encouraging. The next test is regulatory, with a planned Change Notification aimed at expanding the device's European label.

The share price move referenced on 23 July 2026 reflects renewed attention to a company operating in a high-need, high-risk area of oncology. For investors, the opportunity rests on translating positive Phase II data and regulatory progress into commercial traction, while the risks around trial scale, regulatory approval and funding remain material. As always, the clinical development and the day-to-day share price should be assessed on their own merits.